Cargando…

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)

BACKGROUND: In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Naomi J, Hill, Elizabeth M, Ng, Siaw Yein, Martin, Richard M, Metcalfe, Chris, Donovan, Jenny L, Evans, Simon, Hughes, Laura J, Davies, Charlotte F, Hamdy, Freddie C, Neal, David E, Turner, Emma L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429825/
https://www.ncbi.nlm.nih.gov/pubmed/25613468
http://dx.doi.org/10.1186/1471-2288-15-6
_version_ 1782371089260740608
author Williams, Naomi J
Hill, Elizabeth M
Ng, Siaw Yein
Martin, Richard M
Metcalfe, Chris
Donovan, Jenny L
Evans, Simon
Hughes, Laura J
Davies, Charlotte F
Hamdy, Freddie C
Neal, David E
Turner, Emma L
author_facet Williams, Naomi J
Hill, Elizabeth M
Ng, Siaw Yein
Martin, Richard M
Metcalfe, Chris
Donovan, Jenny L
Evans, Simon
Hughes, Laura J
Davies, Charlotte F
Hamdy, Freddie C
Neal, David E
Turner, Emma L
author_sort Williams, Naomi J
collection PubMed
description BACKGROUND: In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers’ ability to correctly guess the trial arm. METHODS: Over 550 General Practitioner (GP) practices (>415,000 men aged 50–69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm. RESULTS: 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation. CONCLUSIONS: It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them. TRIAL REGISTRATION: ISRCTN92187251 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2288-15-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4429825
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44298252015-05-14 Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer) Williams, Naomi J Hill, Elizabeth M Ng, Siaw Yein Martin, Richard M Metcalfe, Chris Donovan, Jenny L Evans, Simon Hughes, Laura J Davies, Charlotte F Hamdy, Freddie C Neal, David E Turner, Emma L BMC Med Res Methodol Research Article BACKGROUND: In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers’ ability to correctly guess the trial arm. METHODS: Over 550 General Practitioner (GP) practices (>415,000 men aged 50–69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm. RESULTS: 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation. CONCLUSIONS: It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them. TRIAL REGISTRATION: ISRCTN92187251 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2288-15-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-01-23 /pmc/articles/PMC4429825/ /pubmed/25613468 http://dx.doi.org/10.1186/1471-2288-15-6 Text en © Williams et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Williams, Naomi J
Hill, Elizabeth M
Ng, Siaw Yein
Martin, Richard M
Metcalfe, Chris
Donovan, Jenny L
Evans, Simon
Hughes, Laura J
Davies, Charlotte F
Hamdy, Freddie C
Neal, David E
Turner, Emma L
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
title Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
title_full Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
title_fullStr Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
title_full_unstemmed Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
title_short Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
title_sort standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from cap (cluster randomised trial of psa testing for prostate cancer)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429825/
https://www.ncbi.nlm.nih.gov/pubmed/25613468
http://dx.doi.org/10.1186/1471-2288-15-6
work_keys_str_mv AT williamsnaomij standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT hillelizabethm standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT ngsiawyein standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT martinrichardm standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT metcalfechris standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT donovanjennyl standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT evanssimon standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT hugheslauraj standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT daviescharlottef standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT hamdyfreddiec standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT nealdavide standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT turneremmal standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer
AT standardisationofinformationsubmittedtoanendpointcommitteeforcauseofdeathassignmentinacancerscreeningtriallessonslearntfromcapclusterrandomisedtrialofpsatestingforprostatecancer